Infectious Disease Advisor1d
Intravenous Immunoglobulin Improves Physical Performance in Post-Polio Patients
Topline data were announced from a phase 2/3 trial evaluating immune globulin intravenous (human) in patients with post-polio syndrome.
Immunovant data positive for Biohaven, says Deutsche Bank
Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Investor's Business Daily on MSN3d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Immunovant's muscle drug meets main goal, shares gain on new drug promise
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
Pulmonology Advisor5d
Wildfire Smoke Exposure May Impair Long-Term COVID-19 Vaccine Immunity
Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.
Medscape5d
Can Antibody Responses to Klebsiella pneumoniae Guide Vaccine Development?
The O-specific polysaccharide of Klebsiella pneumoniae in patients with bloodstream infections is immunogenic, and its closely related subtypes are cross-reactive.